Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (335K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Davies, N. P.
Right arrow Articles by Murray, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, N. P.
Right arrow Articles by Murray, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2000, Vol. 28, No. 15 2954-2958
© 2000 Oxford University Press

The effect of chromatin structure on cisplatin damage in intact human cells

Neil P. Davies, Leigh C. Hardman and Vincent Murray*

School of Biochemistry and Molecular Genetics, University of New South Wales, Sydney, NSW 2052, Australia

The influence of chromatin structure on cisplatin DNA damage was investigated in intact human cells. The epsilon-globin gene promoter was utilised as the target DNA sequence and the terminal transferase-dependent PCR technique was employed to examine adduct formation at base pair resolution. It was found that cisplatin preferentially damaged at runs of consecutive guanine bases in intact cells. By comparing the relative intensity of adduct formation in intact cells and in purified genomic DNA, it was possible to assess the influence of chromatin proteins on the extent of cisplatin DNA damage. Enhanced damage in intact cells was found at the CACC site where a member of the Sp1 family of proteins is thought to bind. It is postulated that protein binding at this site bends the DNA double-helix so that enhanced cisplatin binding occurs. The altered DNA binding of cisplatin in the presence of chromatin proteins could be important in the properties of cisplatin as an anti-tumour drug.

* To whom correspondence should be addressed. Tel: +61 2 9385 2028; Fax: +61 2 9385 1483; Email: v.murray@unsw.edu.au


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. Hamimes, H. Arakawa, A. Z. Stasiak, A. M. Kierzek, S. Hirano, Y.-G. Yang, M. Takata, A. Stasiak, J.-M. Buerstedde, and E. Van Dyck
RDM1, a Novel RNA Recognition Motif (RRM)-containing Protein Involved in the Cell Response to Cisplatin in Vertebrates
J. Biol. Chem., March 11, 2005; 280(10): 9225 - 9235.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
J. Vadolas, H. Wardan, M. Orford, R. Williamson, and P. A. Ioannou
Cellular genomic reporter assays for screening and evaluation of inducers of fetal hemoglobin
Hum. Mol. Genet., January 15, 2004; 13(2): 223 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
S. R. Jaffrey and S. H. Snyder
The Biotin Switch Method for the Detection of S-Nitrosylated Proteins
Sci. Signal., June 12, 2001; 2001(86): pl1 - pl1.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.